Oncology Biosimilars Market

• G-CSF
• Monoclonal Antibody
• Hematopoietic Agents

• Breast Cancer
• Non-Small Cell Lung Cancer
• Blood Cancer
  • Leukemia
    • Myeloid Leukemia
    • Chronic Lymphocytic Leukemia
    • Others
  • Non-Hodgkin Lymphoma
• Colorectal Cancer
• Neutropenia
• Others

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

• North America
• Europe
• Asia Pacific
• Rest of the World

• Sandoz International GmbH
• Pfizer, Inc.
• Celltrion Inc.
• Dr. Reddy’s Laboratories Ltd.
• Biocon
• Teva Pharmaceutical Industries Ltd.
• STADA Arzneimittel AG
• Apotex Inc. (Apobiologix)
• Intas Pharmaceuticals Ltd.
• BIOCAD

Table 01: Global Market Snapshot

Table 02: Global Market Size (USD Million) Forecast, by Drug Class, 2025 to 2035

Table 03: Global Market Size (USD Million) Forecast, by Disease Indication, 2025 to 2035

Table 04: Global Market Size (USD Million) Forecast, Blood Cancer, 2025 to 2035

Table 05: Global Market Size (USD Million) Forecast, by Leukemia, 2025 to 2035

Table 06: Global Market Size (USD Million) Forecast, by Distribution Channel, 2025 to 2035

Table 07: Global Market Size (USD Million) Forecast, by Region, 2025 to 2035

Table 08: Approved by USFDA in new biosimilars pathway established under BPCIA Act

Table 09: North America Pipeline Overview, 2017 to 2020

Table 10: North America Market Size (USD Million) Forecast, by Country, 2025 to 2035

Table 11: North America Market Size (USD Million) Forecast, by Distribution Channel, 2025 to 2035

Table 12: Europe Market Size (USD Million) Forecast, by Country, 2025 to 2035

Table 13: Europe Market Size (USD Million) Forecast, by Drug Class, 2025 to 2035

Table 14: Europe Market Size (USD Million) Forecast, by Disease Indication, 2025 to 2035

Table 15: Europe Market Size (USD Million) Forecast, by Blood Cancer, 2025 to 2035

Table 16: Europe Market Size (USD Million) Forecast, by Leukemia, 2025 to 2035

Table 17: Europe Market Size (USD Million) Forecast, by Distribution Channel, 2025 to 2035

Table 18: Asia Pacific Market Size (USD Million) Forecast, by Country, 2025 to 2035

Table 19: Asia Pacific Market Size (USD Million) Forecast, by Drug Class, 2025 to 2035

Table 20: Asia Pacific Market Size (USD Million) Forecast, by Disease Indication, 2025 to 2035

Table 21: Asia Pacific Market Size (USD Million) Forecast, by Blood Cancer, 2025 to 2035

Table 22: Asia Pacific Market Size (USD Million) Forecast, by Leukemia, 2025 to 2035

Table 23: Asia Pacific Market Size (USD Million) Forecast, by Distribution Channel, 2025 to 2035

Table 24: Rest of the World Market Size (USD Million) Forecast, by Country, 2025 to 2035

Table 25: Rest of the World Market Size (USD Million) Forecast, Drug Class, 2025 to 2035

Table 26: Rest of the World Market Size (USD Million) Forecast, by Disease Indication, 2025 to 2035

Table 27: Rest of the World Market Size (USD Million) Forecast, by Blood Cancer, 2025 to 2035

Table 28: Rest of the World Market Size (USD Million) Forecast, by Leukemia, 2025 to 2035

Table 29: Rest of the World Market Size (USD Million) Forecast, by Distribution Channel, 2025 to 2035

Fig. 01: Global Market Size (USD Million) Forecast, 2025 to 2035

Fig. 02: Global Market Value Share, by Drug Class (2024)

Fig. 03: Global Market Value Share, by Disease Indication (2024)

Fig. 04: Global Market Value Share, by Distribution Channel (2024)

Fig. 05: Global Market Value Share, by Region (2024)

Fig. 06: USA Prevalence Share (%), By Cancer Type, 2020

Fig. 07: Global Estimation of Cancer, By New Cases & Deaths, 2024

Fig. 08: Global Market Value Share, by Drug Class, 2025 and 2035

Fig. 09: Global Market Attractiveness, by Drug Class, 2025 to 2035

Fig. 10: Global Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, by Monoclonal Antibody, 2025 to 2035

Fig. 11: Global Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, by Hematopoietic Agents, 2025 to 2035

Fig. 12: Global Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, by G-CSF, 2025 to 2035

Fig. 13: Global Market Value Share, by Disease Indication, 2025 and 2035

Fig. 14: Global Market Attractiveness, by Disease Indication, 2025 to 2035

Fig. 15: Global Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, by Breast Cancer, 2025 to 2035

Fig. 16: Global Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, by Non-small Cell Lung Cancer, 2025 to 2035

Fig. 17: Global Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, by Blood Cancer, 2025 to 2035

Fig. 18: Global Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, by Colorectal Cancer, 2025 to 2035

Fig. 19: Global Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, by Neutropenia, 2025 to 2035

Fig. 20: Global Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, by Others, 2025 to 2035

Fig. 21: Global Market Value Share, by Distribution Channel, 2025 and 2035

Fig. 22: Global Market Attractiveness, by Distribution Channel, 2025 to 2035

Fig. 23: Global Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, by Online Pharmacy, 2025 to 2035

Fig. 24: Global Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, by Retail Pharmacy, 2025 to 2035

Fig. 25: Global Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacy, 2025 to 2035

Fig. 26: Global Market Value Share, by Region, 2025 and 2035

Fig. 27: Global Market Attractiveness, by Region, 2025 to 2035

Fig. 28: North America Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, 2025 to 2035

Fig. 29: North America Market Value Share, by Country, 2025 and 2035

Fig. 30: North America Market Attractiveness, by Country, 2025 to 2035

Fig. 31: North America Market Value Share, by Distribution Channel, 2025 and 2035

Fig. 32: North America Market Attractiveness, by Distribution Channel, 2025 to 2035

Fig. 33: Europe Market Revenue (USD Million) and Y-o-Y Growth (%) Forecast, 2025 to 2035

Fig. 34: Europe Market Value Share, by Country, 2025 and 2035

Fig. 35: Europe Market Attractiveness, by Country, 2025 to 2035

Fig. 36: Europe Market Value Share, by Drug Class, 2025 and 2035

Fig. 37: Europe Market Attractiveness, by Drug Class, 2025 to 2035

Fig. 38: Europe Market Value Share, by Disease Indication, 2025 and 2035

Fig. 39: Europe Market Attractiveness, by Disease Indication, 2025 to 2035

Fig. 40: Europe Market Value Share, by Distribution Channel, 2025 and 2035

Fig. 41: Europe Market Attractiveness, by Distribution Channel, 2025 to 2035

Fig. 42: Asia Pacific Market Size (USD Million) Forecast and Y-o-Y Growth (%), 2025 to 2035

Fig. 43: Asia Pacific Market Value Share, by Country, 2025 and 2035

Fig. 44: Asia Pacific Oncology Biosimilars, Market Attractiveness, by Country, 2025 to 2035

Fig. 45: Asia Pacific Market Value Share, by Drug Class, 2025 and 2035

Fig. 46: Asia Pacific Market Attractiveness, by Drug Class, 2025 to 2035

Fig. 47: Asia Pacific Market Value Share, by Disease Indication, 2025 and 2035

Fig. 48: Asia Pacific Market Attractiveness, by Disease Indication, 2025 to 2035

Fig. 49: Asia Pacific Market Value Share, by Distribution Channel, 2025 and 2035

Fig. 50: Asia Pacific Market Attractiveness, by Distribution Channel, 2025 to 2035

Fig. 51: Rest of the World Oncology Biosimilars, Market Size (USD Million) Forecast and Y-o-Y Growth (%), 2025 to 2035

Fig. 52: Rest of the World Market Value Share, by Country, 2025 and 2035

Fig. 53: Rest of the World Oncology Biosimilars, Market Attractiveness, by Country, 2025 to 2035

Fig. 54: Rest of the World Market Value Share, by Drug Class, 2025 and 2035

Fig. 55: Rest of the World Market Attractiveness, by Drug Class, 2025 to 2035

Fig. 56: Rest of the World Market Value Share, by Disease Indication, 2025 and 2035

Fig. 57: Rest of the World Market Attractiveness, by Disease Indication, 2025 to 2035

Fig. 58: Rest of the World Market Value Share, by Distribution Channel, 2025 and 2035

Fig. 59: Rest of the World Market Attractiveness, by Distribution Channel, 2025 to 2035

Fig. 60: Global Market Share, by Company, 2024

Fig. 61: Breakdown of Net Sales of Sandoz International GmbH (A Novartis Division), by Franchise, 2024 (%)

Fig. 62: Revenue (USD Billion) & Y-o-Y Growth (%) of Sandoz International GmbH (A Novartis Division), 2020 to 2024

Fig. 63: Breakdown of Net Sales of Pfizer, Inc., by Region, 2024 (%)

Fig. 64: Revenue (USD Billion) & Y-o-Y Growth (%) of Pfizer, Inc., 2020 to 2024

Fig. 65: Breakdown of Net Sales of Celltrion Inc., by Business Segments, 2024

Fig. 66: Revenue (USD Million) & Y-o-Y Growth (%) of Celltrion Inc., 2020 to 2024

Fig. 67: Breakdown of Net Sales of Dr. Reddy’s Laboratories Ltd., by Business Segments, 2024 (%)

Fig. 68: Revenue (USD Billion) & Y-o-Y Growth (%) of Dr. Reddy’s Laboratories Ltd., 2020 to 2024

Fig. 69: Breakdown of Net Sales of Biocon, by Business Segments, 2024 (%)

Fig. 70: Revenue (USD Million) & Y-o-Y Growth (%) of Biocon, 2020 to 2024

Fig. 71: Breakdown of Net Sales of Teva Pharmaceutical Industries Ltd., by Business Segments, 2024 (%)

Fig. 72: Revenue (USD Billion) & Y-o-Y Growth (%) of Teva Pharmaceutical Industries Ltd., 2020 to 2024

Fig. 73: Breakdown of Net Sales of STADA Arzneimittel AG, by Business Segments, 2024 (%)

Fig. 74: Revenue (USD Billion) & Y-o-Y Growth (%) of STADA Arzneimittel AG, 2020 to 2024

Fig. 75: Revenue (USD Million) & Y-o-Y Growth (%) of Intas Pharmaceuticals Ltd., 2020 to 2024